Shandong Xinhua Pharmaceutical Company Limited operates within the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Shandong Xinhua Pharmaceutical Company Limited with three other
companies in this sector in CHINA :
Tianjin Chase Sun Pharmaceutical Company Limited
sales of 5.00 billion Chinese Renmimbi [US$732.83 million]
of which 54%
Changjiang Runfa Medicine Co Ltd
(5.07 billion Chinese Renmimbi [US$743.08 million]
of which 71%
was Medicine), and
Shanxi Zhendong Pharmaceutical Co Ltd
(4.40 billion Chinese Renmimbi [US$644.33 million]
of which 107%
was Medicine Manufacture and Sale).
During the year ended December of 2019, sales at
Shandong Xinhua Pharmaceutical Company Limited were 5.61 billion Chinese Renmimbi (US$821.17 million).
increase of 7.6%
versus 2018, when the company's sales were 5.21 billion Chinese Renmimbi.
This was the fifth consecutive year of sales increases at Shandong Xinhua Pharmaceutical Company Limited
(and since 2014, sales have increased a total of 59%).
Sales of Preparations saw an increase
that was more than double the company's growth rate: sales were up
23.3% in 2019, from
2.58 billion Chinese Renmimbi to 3.18 billion Chinese Renmimbi.